Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
NRG Oncology
Ohio State University Comprehensive Cancer Center
Stanford University
Mayo Clinic
Emory University
OHSU Knight Cancer Institute
Emory University
University of Southern California
University of Michigan Rogel Cancer Center
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group